{"id":"W4225630787","doi":"10.1093/neuonc/noac116","title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":501,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Temozolomide; Medicine; Internal medicine; Nivolumab; Placebo; Regimen; Dacarbazine; Chemoradiotherapy; Gastroenterology; Radiation therapy; Progression-free survival; Randomized controlled trial; Clinical endpoint; Chemotherapy; Oncology; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003058496,0.0003753034,0.001361883,0.0002541448,0.0001948494,0.00001484698,0.0001935784,0.0001426254,0.0003785225],"category_scores_gemma":[0.0001237619,0.000248095,0.000177404,0.0005570769,0.0001848091,0.0000709279,0.00006135564,0.0003367811,0.000002805762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005541247,"about_ca_system_score_gemma":0.001224123,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008511265,"about_ca_topic_score_gemma":0.000231287,"domain_scores_codex":[0.9975713,0.0002669261,0.0005672855,0.0006549466,0.0004310805,0.0005084507],"domain_scores_gemma":[0.9975022,0.001109173,0.0004776094,0.0005143243,0.0001711811,0.0002255026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8094104,0.0111051,0.0001607611,0.00007404303,0.0007013698,0.00328539,0.0008726465,0.0001720903,0.1446401,0.00002423754,0.006758519,0.02279535],"study_design_scores_gemma":[0.622959,0.1923207,0.00001685218,0.0000261929,0.0006144408,0.0008605435,0.0002508545,0.0006054447,0.1191946,0.000008517837,0.06292647,0.0002163592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886506,0.0001229401,0.0001565587,0.003337775,0.0003443368,0.006855661,0.00009760176,0.0001125582,0.0003219645],"genre_scores_gemma":[0.9908264,0.00004177828,0.002129997,0.001932222,0.0002360331,0.004501234,0.00007587551,0.000123226,0.0001332296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1864514,"threshold_uncertainty_score":0.9999971,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02156685144926639,"score_gpt":0.3125214745721496,"score_spread":0.2909546231228832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}